Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 3
Submit an article Journal homepage
101
Views
17
CrossRef citations to date
0
Altmetric
Reviews

Spontaneous and treatment-induced cancer rejection in humans

Ena Wang Director Molecular Sciences National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
, MD,
Silvia Selleri University of Milan, Department of Human Morphology, Milan, Italy
, PhD,
Marianna Sabatino National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
, MD,
Alessandro Monaco National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA; National Cancer Institute, Clinical Experimental Oncology Laboratory, Giovanni Paolo II Bari, Italy
, PhD,
Zoltan Pos National Institutes of Health, Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
, PhD,
Andrea Worschech Genelux Corporation, San Diego Science Center, San Diego, CA, USA; University of Würzburg, Department of Biochemistry, Biocenter, Am Hubland, Würzburg, Germany
, PhD,
David F Stroncek Chief, Cell Processing Section, National Institutes of Health, Department of Transfusion Medicine, Clinical Center, Bethesda, Maryland, 20892, USA
, MD &
Francesco M Marincola Chief, Infectious Disease and Immunogenetics Section, National Institutes of Health, Department of Transfusion Medicine, Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, USA +1 301 451 4967; +1 301 402 1360;[email protected]
, MD show all
Pages 337-349 | Published online: 25 Feb 2008

Bibliography

  • Urban JL, Van Waes C, Schreiber H. Pecking order among tumor-specific antigens. Eur J Immunol 1984;14(2):181-7
  • Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004;10(3):294-8
  • Baurain JF, Colau D, van Baren N, et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol 2000;164(11):6057-66
  • Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183(3):1185-92
  • Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18(6):267-8
  • Kawakami Y, Rosenberg SA. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1996;15(3):179-90
  • Parmiani G, Anichini A, Castelli C. New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses. Melanoma Res 1997;7(Suppl 2):S95-8
  • Dankers MK, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004;77(8):1236-9
  • Duquesnoy RJ, Marrari M. Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: a report of a collaborative study conducted during the 12th International Histocompatibility Workshop. Transplantation 1997;63(12):1743-51
  • Jin P, Wang E. Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J Transl Med 2003;1:8
  • Van Der Bruggen P. van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006;18(1):98-104
  • Dalgleish A, Pandha H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv Cancer Res 2007;96:175-90
  • Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007;360:319-26
  • Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007;178(4):1975-9
  • Old LJ, Chen YT. New Paths in Human Cancer Serology. J Exp Med 1998;187(8):1163-7
  • Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315(26):1650-9
  • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357(9255):539-45
  • Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophage as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23(11):549-55
  • Mantovani A. Cancer: inflammation by remote control. Nature 2005;435(7043):752-3
  • Mantovani A, Romero P, Palucka AK, Marincola FM. Tumor immunity: effector response to tumor and the influence of the microenvironment. Lancet 2008;In press
  • Deonarine K, Panelli MC, Stashower ME, et al. Gene expression profiling of cutaneous wound healing. J Transl Med 2007;5:11
  • Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211-7
  • De Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7(5):411-23
  • Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354(7):709-18
  • Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63
  • Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991;68:2384-90
  • Atkins MB. Autoimmune disorders induced by Interleukin-2 therapy. In: Therapeutic Applications of Interleukin-2. 1st edition. Atkins MB, Mier JW, editors. New York: Dekker, Inc.; 1993. p. 389-408
  • Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-9
  • Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991;16:303-5
  • Mehta N, Ramming K, Richards JM. Treatment-induced vitiligo during successful chemoimmunotherapy for melanoma. Proc Annu Meet Am Soc Clin Oncol 1991;10:A1018
  • Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19(1):81-4
  • Overwijk WW, Lee DS, Surman DR, et al. Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-7
  • Uchi H, Stan R, Turk MJ, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006;90:215-41
  • Wang E, Panelli MC, Zavaglia K, et al. Melanoma-restricted genes. J Transl Med 2004;2:34
  • Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol 2006;12(42):6741-6
  • Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor κB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000;31(3):656-64
  • Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett 2005;229(2):157-69
  • Wang E, Ngalame Y, Panelli MC, et al. Peritoneal and sub-peritoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005;11(1):113-22
  • Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27
  • Barry JM, Rosenberg SA. The Transformed Cell: Unlocking the Mysteries of Cancer. 1st edition. New York, NY: GP Putnam's Sons; 1992
  • Davis SD, Koizumi JH, Pitts WR. Spontaneous regression of pulmonary metastases from renal cell carcinoma. Urology 1989;33(2):141-4
  • Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20(4):416-8
  • Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 2003;170(1):178-9
  • Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11
  • Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005;56(1):71-85
  • Ippoliti G, Rinaldi M, Pellegrini C, Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 2005;56(1):101-13
  • Vallejo GH, Romero CJ, de Vicente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005;56(1):87-99
  • Ghelani D, Saliba R, Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 2005;56(1):115-26
  • Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005;56(1):155-67
  • Rooney CM, Roskrow MA, Smith CA, et al. Immunotherapy of Epstein-Barr virus-associated cancer. J Natl Cancer Inst Monogr 1998;23:89-93
  • Green M. Management of Epstein-Barr virus-induced post-tranplant lymphoproliferative disease in recipients of solid organ transplanation. Am J Transplant 2001;1(2):103-8
  • Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997;157:217-22
  • Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epsten-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96(18):10391-6
  • Haque T, Taylor C, Wilkie GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001;72(8):1399-402
  • Gottschalk S, Heslop HE, Rooney CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002;84:175-201
  • Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg 2007;33(8):885-99
  • Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3(11):991-8
  • Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004;22:329-60
  • Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21(2):137-48
  • Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351(21):2159-69
  • Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
  • Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66
  • Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
  • Torisu-Itakura H, Lee JH, Scheri RP, et al. Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res 2007;13(11):3125-32
  • Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006;4:50. Published online 27 November 2006; doi:10.1186/1479-5876-4-50
  • Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1998;17(7):2105-16
  • Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10(18 Pt 2):S6342-6
  • Malyankar UM. Tumor-associated antigens and biomarkers in cancer and immune therapy. Int Rev Immunol 2007;26(3-4):223-47
  • Atkins MB, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome in interleukin-2 therapy of renal cancer. Clin Cancer Res 2005;11(10):3714-21
  • Panelli MC, Wang E, Marincola FM. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res 2005;11(10):3601-3
  • Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29(4):455-63
  • Small EJ, Tchekmedyian NS, Rini B, et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007;13(6):1810-5
  • O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13(3):958-64
  • Hansson M, Bakacs KK, Kiessling R, Klein G. Intra- and interspecies reactivity of human and mouse natural killer (NK) cells. J Immunol 1978;121(1):6-12
  • Gronberg A, Kiessling R, Masucci G, et al. Gamma-interferon (IFN-γ) produced during effector and target interactions renders target cells less susceptible to NK-cell-mediated lysis. Int J Cancer 1983;32(5):609-16
  • Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002;55(3):221-8
  • Chan CW, Crafton E, Fan HN, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006;12(2):207-13
  • Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11
  • Moretta A, Sivori S, Ponte M, et al. Stimulatory receptors in NK and T cells. Curr Top Microbiol Immunol 1998;230:15-23
  • Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells. Ann Rev Immunol 1996;14:619-48
  • Moretta L, Bottino C, Pende D, et al. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006;18(3):151-8
  • Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 1991;9:1233-40
  • Dutcher JP, Gaynor ER, Boldt DH, et al. A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 19919:641-648.
  • Fisher RI, Coltman CA Jr, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A Phase II clinical trial. Ann Intern Med 1988;108:518-23
  • Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Published erratum appears in J Natl Cancer Inst 1993;85(13):1091; J Natl Cancer Inst 1993;85:622-32
  • Ochsenbein AF, Klenerman P, Karrer U, et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-8
  • Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Sem Immunol 2000;12:163-71
  • Lang KS, Recher M, Junt T, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 2005;11(2):138-45
  • Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109(12):5346-54
  • Hicks AM, Riedlinger G, Willingham MC, et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci USA 2006;103(20):7753-8
  • Wolfel T, Klehmann E, Muller C, et al. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170:797-810
  • Kawakami Y, Zakut R, Topalian SL, et al. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992;148:638-43
  • Salgaller ML, Afshar A, Marincola FM, et al. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9
  • Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992;50:289-97
  • Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65
  • Marincola FM, Rivoltini L, Salgaller ML, et al. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence for in vivo priming by tumor cells. J Immunother 1996;19(4):266-77
  • D'Souza S, Rimoldi D, Lienard D, et al. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer 1998;78(6):699-706
  • van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7
  • Rosenberg SA, Kawakami Y, Robbins PF, Wang R. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 1996;70:145-77
  • Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3(1):37-44
  • Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57
  • Lee K-H, Wang E, Nielsen M-B, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292-300
  • Monsurro' V, Wang E, Yamano Y, et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004;104(7):1970-8
  • Monsurro' V, Wang E, Panelli MC, et al. Active-specific immunization against melanoma: is the problem at the receiving end? Sem Cancer Biol 2003;13(6):473-80
  • Marincola FM, Ferrone S. Immunotherapy of melanoma: the good news, the bad news and what to do next. Sem Cancer Biol 2003;13(6):387-9
  • Marincola FM. A balanced review of the status of T cell-based therapy against cancer. J Transl Med 2005;3(1):16
  • Mocellin S, Mandruzzato S, Bronte V, Marincola FM. Correspondence 1: cancer vaccines: pessimism in check. Nat Med 2004;10(12):1278-9
  • Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15
  • Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005;436(7053):961-6
  • Lau CY, Velasco PP, Johnston MI. A new era in HIV vaccine development. Expert Rev Antiinfect Ther 2007;5(2):205-15
  • Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25(20):2975-82
  • Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8(5):271-80
  • Clynes R, Takechi Y, Moroi Y, et al. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 1998;95(2):652-6
  • Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195(1):125-33
  • Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(5 Suppl 14)):66-73
  • Ismael G, Rosa DD, de Azambuja E, et al. Trastuzumab (Herceptin) for early-stage breast cancer. Hematol Oncol Clin North Am 2007;21(2):239-56
  • Shan BE, Hao JS, Li QX, Tagawa M. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol 2006;3(1):47-52
  • Hao JS, Shan BE. Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother 2006;55(11):1426-31
  • Overwijk WW, De Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol 2006;176(9):5213-22
  • Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442(7101):461-5
  • Oniki S, Nagai H, Horikawa T, et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006;66(12):6395-404
  • Hu J, Yuan X, Belladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006;66(17):8887-96
  • Mocellin S, Panelli MC, Wang E, et al. The dual role of IL-10. Trends Immunol 2002;24(1):36-43
  • Mocellin S, Nitti D. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Med Res Rev 2007;In Press
  • Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273
  • Marincola FM, Wang E, Herlyn M, et al. Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 2003;24(6):335-42
  • Rees J. Complex disease and the new clinical sciences. Science 2002;296(5568):698-700
  • Wang E, Marincola FM. A natural history of melanoma: serial gene expression analysis. Immunol Today 2000;21(12):619-23
  • Wang E, Panelli MC, Marincola FM. Gene profiling of immune responses against tumors. Curr Opin Immunol 2005;17(4):423-7
  • Wang E, Panelli M, Marincola FM. Autologous tumor rejection in humans: trimming the myths. Immunol Invest 2006;35(3-4):437-58
  • Wang E, Panelli MC, Monsurro' V, Marincola FM. Gene expression profiling of anti-cancer immune responses. Curr Opin Mol Ther 2004;6(3):288-95
  • Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6
  • Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3(7):RESEARCH0035
  • Panelli MC, Stashower M, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with Imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8(1):R8
  • Panelli MC, Martin B, Nagorsen D, et al. A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2003;177(3):124-31
  • Panelli MC, White RL Jr, Foster M, et al. Forecasting the cytokine storm following systemic interleukin-2 administration. J Transl Med 2004;2:17
  • Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349(2):125-38
  • Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5(3):215-29
  • Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001;75(15):7059-66
  • Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004;78(24):13779-92
  • Smith MW, Yue ZN, Korth MJ, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 2003;38(6):1458-67
  • Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFα. Immunity 2005;22(1):131-42
  • Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005;102(45):16309-14
  • Cagnard N, Letourneur F, Essabbani A, et al. Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005;16(4):289-92
  • Shoda H, Fujio K, Yamamoto K. Rheumatoid arthritis and interleukin-32. Cell Mol Life Sci 2007;64(19-20):2671-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.